ArticleBDJ open2026
Biological effects of N-acetylcysteine, calcium hydroxide, chlorhexidine and their combinations as intracanal medications: cytotoxicity, genotoxicity and cytokine modulation.
Article in BDJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to evaluate whether the combination of N-acetylcysteine (NAC), a compound with antimicrobial, antioxidant, and immunomodulatory properties, with conventional intracanal medications calcium hydroxide [Ca(OH)₂] and chlorhexidine (CHX) alters their biological effects on murine macrophage cells (RAW 264.7) and human osteoblasts-like cells (MG-63), with particular emphasis on cytotoxicity, genotoxicity, and cytokine production. MATERIALS AND
methodsThe study groups were control group of Dulbecco's Modified Eagle Medium (DMEM), Ca(OH)₂ (100 mg/100 µL saline solution), 2% CHX gel (100 µL), NAC (100 mg/100 µL saline solution), NAC + Ca(OH)₂ (50 + 50 mg/100 µL saline solution), NAC + CHX (100 mg/100 µL 2% CHX gel), Ca(OH)₂ + CHX (100 mg/100 µL 2% CHX gel), and NAC + Ca(OH)₂ + CHX (50 + 50 mg/100 µL 2% CHX gel). The preparations were conditioned in culture medium for 24 h, and 100 µL of the resulting conditioned medium was used for cell exposure. Cytotoxicity was evaluated by MTT colorimetric assay that measures the metabolic activity of the cells after 5 min and 24 h. Genotoxicity was evaluated by cytokinesis-block micronucleus assay after 24 h with Ethyl methanesulfonate (EMS) as control group. In addition, cytometry bead arrays to quantify different cytokine production by RAW 264.7 and MG63 cells under LPS-stimulated conditions. Data were statistically analyzed with a significant level of α ≤ 0.05.
resultsMost experimental groups maintained metabolic activity comparable to the control group in both cell lines, although NAC, NAC + CHX, and Ca(OH)₂ + CHX reduced RAW 264.7 metabolic activity after 24 h. Most experimental groups showed significantly lower micronucleus frequency in RAW 264.7 and MG-63 cells compared with the EMS positive control group (P < 0.0001). However, the CHX group in RAW 264.7 cells exhibited a micronucleus frequency that was not significantly different from the EMS group. Still, NAC increased IL-12p70, IL-6, IFN-γ, and IL-10 production in RAW 264.7, and increased IL-12p70, TNF-α, IL-10, IL-6, and IL-1β levels in MG-63.
conclusionNAC modulated cytokine production in both cell models under LPS-stimulated conditions, resulting in a mixed profile of pro-inflammatory and regulatory mediators rather than a purely anti-inflammatory response. Most tested medications maintained acceptable metabolic activity and low genotoxic potential under the evaluated conditions, although CHX increased micronucleus formation in RAW 264.7 cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.